UNSPSC 51351501: Chlormadinone

This classification denotes a therapeutic progestin with the molecular formula C21H27ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SDS4N642GG, chemically known as 17.alpha.-acetoxy-6-chloro-4, 6-pregnadiene-3,20-dione but generally known as chlormadinone, which bears US NIH Compound Identifier 2714. European Medicines Agency schedules Chlormadinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06183MIG.

UNSPSC 51351501 Chlormadinone, a Commodity code, encompasses generic pharmaceutical products supplied through state and local government cooperative purchasing vehicles, specifically multi-source medications and over-the-counter products distributed via authorized wholesale channels to public health facilities. State and local governments procure under this code primarily through multistate cooperative purchasing alliances rather than individual jurisdictional RFPs; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the dominant issuing structure for this commodity class. Suppliers must meet rigorous regulatory and operational requirements, including current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, established relationships with authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), electronic data interchange capability, and comprehensive insurance including $5,000,000 commercial general liability per occurrence. Vendors provide detailed product specifications including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, and packaging configuration, with pricing submitted through multiple formats (flat price, net price, or WAC-minus structures) and subject to a 3 percent administrative fee on all purchases.

MMCAP's February 2026 RFP for generic multi-source pharmaceuticals and OTC products spans participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The cooperative purchasing model allows awarded vendors to supply products through designated wholesalers beginning July 1, 2026, with contract terms of two years for new responders and optional extensions at MMCAP's discretion. Evaluation emphasizes price competitiveness (75 percent weight), administrative compliance (10 percent), EDI capability (5 percent), fee acceptance (5 percent), and pricing format (5 percent); specific award values are not disclosed. Vendors face performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding timelines, or class-of-trade denials, and all products must comply with FDA requirements and maintain minimum six-month shelf life from the contract effective date.